ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Dow and Shell will receive $4.2 million in funding from the Dutch government toward their work in electrically heated ethylene steam-cracking furnaces. The companies say they are evaluating the construction of a pilot plant by 2025, “subject to investment support.”
Tosoh will spend $90 million to renovate and expand its Tokyo Research Center in Ayase, Japan. The firm says the project, set for completion in 2026, will include a building for advanced organic materials research.
Johnson Matthey, Thomas Swan, and the UK technology agency CPI are investigating ways to increase the performance of Johnson Matthey’s lithium-ion battery materials using carbon nanotubes and graphene nanoplatelets. The project will receive funding from the UK government’s Faraday Battery Challenge.
Invista plans to build a nylon 6,6 technology application center in Shanghai at a cost of $15 million. The center will undertake analytical and mechanical testing of engineering polymers for markets including automotive and electronics.
Yara International and other are investing $4 million in Boomitra, a Silicon Valley start-up with a method for monitoring carbon levels in the soil without the need for physical soil samples. The technique is meant to help small-scale farmers access carbon-credit markets.
Lonza will help Selectimmune Pharma develop a process for manufacturing its immunotherapy protein NlpD. Lonza has also agreed to make ValenzaBio’s anti-insulin-like growth factor-1 receptor antibody to treat thyroid eye disease and other inflammatory disorders.
Viiv Healthcare is paying $40 million to Halozyme Therapeutics for exclusive use of Halozyme drug delivery technology based on human hyaluronidase PH20 enzyme. The goal is injectable HIV treatments that last longer than 3 months.
Veralox Therapeutics has raised $16.6 million in series A financing to develop small-molecule inhibitors of the enzyme 12-lipoxygenase. The start-up plans to test the compounds on a blood clot disorder called heparin-induced thrombocytopenia.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter